Hospital

A randomized study of renin-angiotensin system inhibitors in advanced chronic kidney disease found that patients who continued receiving therapy had similar outcomes to those who discontinued treatment.

There are limited data on the efficacy of boosters for preventing infection and death in nursing home residents, but the findings suggest that boosters may have significantly reduced COVID-19–associated morbidity and mortality in this population.

Study findings provide insight into factors preventing the uptake of pre-exposure prophylaxis for HIV among Black female adolescents and emerging adults and provide potential strategies to improve uptake.

Although quality of life has significantly improved for patients with HIV, there are several factors influencing how we provide care and treat patients now and in the future.

While the use of direct-acting antiviral treatment for hepatitis C virus increased from 2014 to 2018, treatment rates have declined since 2019 and remain suboptimal.

Ponatinib could be the first targeted treatment approved in the United States for Philadelphia chromosome-positive acute lymphoblastic leukemia.

Following the positive phase 3 results, GSK anticipates regulatory submissions in the first half of 2023.

The updated recommendations during a surge in cases emphasize the need to enhance emergency readiness daily to not interrupt continuous care of children’s mental and physical well-being.

Although progress has been made in pre-exposure prophylaxis use, there are still significant barriers for many patients.

Despite a limited understanding about access to oral anticancer drugs, new research finds challenges in patient and clinician decision-making.

The American Heart Association said that yoga, tai-chi, and certain alternative medicines may be beneficial for heart failure, whereas other products may be harmful.

Expert discusses the patient-reported outcomes from the GRIFFIN trial at the final study analysis after all patients completed 1 year of follow-up post maintenance therapy.

Expert discusses updated cohort of patients with longer-term follow up treated in the phase 2 clinical trial of venetoclax added to cladribine plus low-dose araC alternating with azacytidine.

Respiratory syncytial virus- and rhinovirus-induced wheezing illnesses differ from each other at multiple levels.

Patient-controlled analgesia typically consists of opioids or local anesthetics, but it may also include non-opioid analgesics or other medications.

Expert discusses the updated data for a trial cohort after a median follow-up of 27 months.

Adagrasib (Krazati; Mirati Therapeutics, Inc) approved for adults with KRAS-G12C-mutated locally advanced or metastatic non-small cell lung cancer as determined by an FDA-approved test.

It remains a challenge to understand how to stratify risk of liver diseases before they have reached the advanced stage.

Based on real-world outcomes, there is an unmet need for an effective therapy to be used among patients aged 75 years or older with relapsed/refractory diffuse large B-cell lymphoma.

Relatives who attend low-intensity coaching and monitoring meetings increase individuals’ ability to manage the disease.

Following the approval of cabotegravir in 2021, governments and donor agencies in low- and middle-income countries are contemplating replacing oral pre-exposure prophylaxis or augmenting the approach with long-acting treatment.

Five crucial steps pharmacies can take to enhance patient engagement and lower operational costs.

Dapagliflozin (Farxiga) found effective in lowering the risk of hospitalization for patients with chronic kidney disease, with or without a diagnosis of type 2 diabetes, and increased the number of days alive and out of the hospital.

Study findings may make durvalumab plus chemotherapy a new standard of care option for patients with advanced biliary tract cancer.

A patient with juvenile dermatomyositis experienced aseptic meningitis brought on by intravenous immunoglobulin and recovered fully with no neurological effects.

Expert discusses the effect of baseline transfusion burden and luspatercept dose level on response to treatment in patients with LR-MDS from the MEDALIST study.

Expert discusses the results of a trial assessing immune reconstitution in adult patients who received Orca-T, consisting of hematopoietic stem/progenitor cells, regulatory T cells, and conventional T cells.

Expert discusses clinical outcomes of the phase 3 ZUMA-7 trial assessing axicabtagene ciloleucel versus standard-of-care in second-line large B-cell lymphoma by metabolic tumor volume.

Expert discusses the safety and efficacy of polatuzumab vedotin combined with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) as second-line treatment in a multicenter phase 2 study.

Expert discusses analysis of phase 3 MEDALIST trial data aimed to assess the probability of greater overall survival and progression-free survival benefit from luspatercept vs placebo.